Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Human leukocyte antigens class II in CIDP spectrum neuropathies.

Cotti Piccinelli S, Carella G, Frassi M, Caria F, Gallo Cassarino S, Baldelli E, Marini M, Tincani A, Padovani A, Filosto M.

J Neurol Sci. 2019 Oct 23;407:116533. doi: 10.1016/j.jns.2019.116533. [Epub ahead of print]

PMID:
31670164
2.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue JY, Gatto S, Fernandez-Banet J, Pavlicek A, Velastegui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG.

Cancer Discov. 2019 Oct 28. pii: CD-19-1167. doi: 10.1158/2159-8290.CD-19-1167. [Epub ahead of print]

PMID:
31658955
3.

A Novel CAPN1 Mutation Causes a Pure Hereditary Spastic Paraplegia in an Italian Family.

Cotti Piccinelli S, Bassi MT, Citterio A, Manganelli F, Tozza S, Santorelli FM, Gallo Cassarino S, Caria F, Baldelli E, Galvagni A, Santoro L, Padovani A, Filosto M.

Front Neurol. 2019 Jun 5;10:580. doi: 10.3389/fneur.2019.00580. eCollection 2019.

4.

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C.

Mol Cancer Res. 2019 Sep;17(9):1815-1827. doi: 10.1158/1541-7786.MCR-19-0191. Epub 2019 Jun 4.

PMID:
31164413
5.

Late and Severe Myopathy in a Patient With Glycogenosis VII Worsened by Cyclosporine and Amiodarone.

Filosto M, Cotti Piccinelli S, Pichiecchio A, Musumeci O, Galvagni A, Caria F, Gallo Cassarino S, Baldelli E, Vitale R, Padovani A, Toscano A.

Front Neurol. 2019 Feb 7;10:77. doi: 10.3389/fneur.2019.00077. eCollection 2019.

6.

A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M.

Acta Diabetol. 2019 Apr;56(4):385-396. doi: 10.1007/s00592-018-1266-0. Epub 2018 Dec 5. Review.

PMID:
30519965
7.

Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE-MTDPS1).

Filosto M, Cotti Piccinelli S, Caria F, Gallo Cassarino S, Baldelli E, Galvagni A, Volonghi I, Scarpelli M, Padovani A.

J Clin Med. 2018 Oct 26;7(11). pii: E389. doi: 10.3390/jcm7110389. Review.

8.

Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?

Nascimbeni F, Romagnoli D, Ballestri S, Baldelli E, Lugari S, Sirotti V, Giampaoli V, Lonardo A.

Diseases. 2018 Feb 16;6(1). pii: E17. doi: 10.3390/diseases6010017.

9.

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.

Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, Bianconi F.

Oncotarget. 2017 Jun 14;8(47):83343-83353. doi: 10.18632/oncotarget.18480. eCollection 2017 Oct 10.

10.

Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.

Br J Cancer. 2017 Aug 8;117(4):494-502. doi: 10.1038/bjc.2017.195. Epub 2017 Jun 29.

11.

Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases.

Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, Lonardo A.

Metabolism. 2017 Jul;72:57-65. doi: 10.1016/j.metabol.2017.04.003. Epub 2017 Apr 13.

PMID:
28641784
12.

NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.

Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A.

Adv Ther. 2017 Jun;34(6):1291-1326. doi: 10.1007/s12325-017-0556-1. Epub 2017 May 19. Review.

13.

Reverse Phase Protein Microarrays.

Baldelli E, Calvert V, Hodge A, VanMeter A, Petricoin EF 3rd, Pierobon M.

Methods Mol Biol. 2017;1606:149-169. doi: 10.1007/978-1-4939-6990-6_11.

PMID:
28502000
14.

Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis.

Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE.

World J Gastroenterol. 2017 Feb 28;23(8):1458-1468. doi: 10.3748/wjg.v23.i8.1458.

15.

A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Pin E, Stratton S, Belluco C, Liotta L, Nagle R, Hodge KA, Deng J, Dong T, Baldelli E, Petricoin E, Pierobon M.

Mol Oncol. 2016 Dec;10(10):1585-1594. doi: 10.1016/j.molonc.2016.09.007. Epub 2016 Oct 14.

16.

Telomere length elongation after weight loss intervention in obese adults.

Carulli L, Anzivino C, Baldelli E, Zenobii MF, Rocchi MB, Bertolotti M.

Mol Genet Metab. 2016 Jun;118(2):138-42. doi: 10.1016/j.ymgme.2016.04.003. Epub 2016 Apr 22.

PMID:
27157420
17.

Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A.

Int J Mol Sci. 2016 Mar 9;17(3):355. doi: 10.3390/ijms17030355. Review.

18.

Erratum to: 'Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology'.

Bianconi F, Baldelli E, Ludovini V, Petricoin EF, Crinò L, Valigi P.

BMC Syst Biol. 2016 Mar 2;10:24. doi: 10.1186/s12918-016-0267-2. No abstract available.

19.

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.

Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Lonardo A.

Adv Ther. 2016 Mar;33(3):291-319. doi: 10.1007/s12325-016-0306-9. Epub 2016 Feb 26. Review.

PMID:
26921205
20.

An approach for optimally extending mathematical models of signaling networks using omics data.

Bianconi F, Patiti F, Baldelli E, Crino L, Valigi P.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:6501-4. doi: 10.1109/EMBC.2015.7319882.

PMID:
26737782
21.

Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.

Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A.

J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264. Review.

PMID:
26667191
22.

Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology.

Bianconi F, Baldelli E, Ludovini V, Petricoin EF, Crinò L, Valigi P.

BMC Syst Biol. 2015 Oct 19;9:70. doi: 10.1186/s12918-015-0216-5. Erratum in: BMC Syst Biol. 2016;10:24. Luovini, Vienna [corrected to Ludovini, Vienna].

23.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M.

Oncotarget. 2015 Oct 20;6(32):32368-79. doi: 10.18632/oncotarget.5941.

24.

Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease.

Gronewold J, Klafki HW, Baldelli E, Kaltwasser B, Seidel UK, Todica O, Volsek M, Haußmann U, Wiltfang J, Kribben A, Bruck H, Hermann DM.

Mol Neurobiol. 2016 Jul;53(5):3136-3145. doi: 10.1007/s12035-015-9218-y. Epub 2015 May 28.

PMID:
26019016
25.

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.

Baldelli E, Haura EB, Crinò L, Cress DW, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M.

Proteomics Clin Appl. 2015 Oct;9(9-10):928-37. doi: 10.1002/prca.201400056. Epub 2015 Mar 24.

26.

Nonalcoholic fatty liver disease and aging: epidemiology to management.

Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P.

World J Gastroenterol. 2014 Oct 21;20(39):14185-204. doi: 10.3748/wjg.v20.i39.14185. Review.

27.

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.

Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M.

Proteomics. 2015 Jan;15(2-3):365-73. doi: 10.1002/pmic.201400214.

PMID:
25311472
28.

Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P.

World J Gastroenterol. 2014 Jun 21;20(23):7089-103. doi: 10.3748/wjg.v20.i23.7089. Review.

29.

Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population.

Bertolotti M, Mussi C, Pellegrini E, Magni A, Del Puppo M, Ognibene S, Carulli L, Anzivino C, Baldelli E, Loria P, Carulli N.

Clin Interv Aging. 2014 Mar 17;9:425-32. doi: 10.2147/CIA.S57714. eCollection 2014.

30.

Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography.

Ballestri S, Meschiari E, Baldelli E, Musumeci FE, Romagnoli D, Trenti T, Zennaro RG, Lonardo A, Loria P.

Metab Syndr Relat Disord. 2013 Aug;11(4):289-95. doi: 10.1089/met.2012.0149. Epub 2013 Apr 19.

PMID:
23600632
31.

In vivo degradation of cholesterol to bile acids is reduced in patients receiving parenteral nutrition.

Carulli L, Del Puppo M, Anzivino C, Zambianchi L, Gabbi C, Baldelli E, Odoardi MR, Loria P, Carulli N, Bertolotti M.

JPEN J Parenter Enteral Nutr. 2014 Feb;38(2):220-6. doi: 10.1177/0148607113476751. Epub 2013 Feb 20.

PMID:
23426743
32.

Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.

Carulli L, Maurantonio M, Hebbard L, Baldelli E, Loria P, George J.

Curr Pharm Des. 2013;19(29):5280-96. Review.

PMID:
23394096
33.

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.

Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, Chiari R, Minotti V, Pistola L, Tofanetti FR, Siggillino A, Baldelli E, Sidoni A, Daddi N, Puma F, Varella-Garcia M, Crinò L.

Cancer Chemother Pharmacol. 2013 Mar;71(3):671-80. doi: 10.1007/s00280-012-2056-y. Epub 2013 Jan 12.

34.

ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population.

Anzivino C, Odoardi MR, Meschiari E, Baldelli E, Facchinetti F, Neri I, Ruggiero G, Zampino R, Bertolotti M, Loria P, Carulli L.

Dig Liver Dis. 2013 Mar;45(3):226-32. doi: 10.1016/j.dld.2012.08.011. Epub 2012 Sep 27.

PMID:
23022423
35.

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.

Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L.

Cancer Chemother Pharmacol. 2012 May;69(5):1289-99. doi: 10.1007/s00280-012-1829-7.

PMID:
22302407
36.

Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.

Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L.

J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f.

37.

Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology.

Bianconi F, Baldelli E, Ludovini V, Crinò L, Flacco A, Valigi P.

Biotechnol Adv. 2012 Jan-Feb;30(1):142-53. doi: 10.1016/j.biotechadv.2011.05.010. Epub 2011 May 18. Erratum in: Biotechnol Adv. 2013 Mar-Apr;31(2):358-60.

PMID:
21620944
38.

Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.

Bertolotti M, Del Puppo M, Corna F, Anzivino C, Gabbi C, Baldelli E, Carulli L, Loria P, Galli Kienle M, Carulli N.

Nutr Metab Cardiovasc Dis. 2012 Oct;22(10):823-30. doi: 10.1016/j.numecd.2011.02.009. Epub 2011 May 4.

PMID:
21546230
39.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

40.

Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment.

Baldelli E, Leo G, Andreoli N, Fuxe K, Biagini G, Agnati LF.

Neuromolecular Med. 2010 Sep;12(3):248-59. doi: 10.1007/s12017-009-8110-1. Epub 2009 Dec 22.

PMID:
20033627
41.

Are maternal mitochondria the selfish entities that are masters of the cells of eukaryotic multicellular organisms?

Agnati LF, Barlow PW, Baldelli E, Baluska F.

Commun Integr Biol. 2009;2(2):194-200.

42.

Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period.

Biagini G, Longo D, Baldelli E, Zoli M, Rogawski MA, Bertazzoni G, Avoli M.

Epilepsia. 2009 Jan;50 Suppl 1:53-8. doi: 10.1111/j.1528-1167.2008.01971.x.

43.

Semisynthesis of new D-seco-C-nor-taxane derivatives containing a polyfunctionalized furanosyl or cyclopentenyl or cyclopentyl C-ring.

Gelmi ML, Nava D, Leone S, Pellegrino S, Baldelli E, Zunino F, Cappelletti G, Cartelli D, Fontana G.

J Org Chem. 2008 Nov 21;73(22):8893-900. doi: 10.1021/jo801458j. Epub 2008 Oct 22.

PMID:
18939872
44.

Proepileptic influence of a focal vascular lesion affecting entorhinal cortex-CA3 connections after status epilepticus.

Biagini G, Baldelli E, Longo D, Contri MB, Guerrini U, Sironi L, Gelosa P, Zini I, Ragsdale DS, Avoli M.

J Neuropathol Exp Neurol. 2008 Jul;67(7):687-701. doi: 10.1097/NEN.0b013e318181b8ae.

45.

On the key role played by altered protein conformation in Parkinson's disease.

Agnati LF, Baldelli E, Andreoli N, Woods AS, Vellani V, Marcellino D, Guidolin D, Fuxe K.

J Neural Transm (Vienna). 2008 Sep;115(9):1285-99. doi: 10.1007/s00702-008-0072-1. Epub 2008 Jun 5. Review.

PMID:
18528629
46.

Network hyperexcitability within the deep layers of the pilocarpine-treated rat entorhinal cortex.

de Guzman P, Inaba Y, Baldelli E, de Curtis M, Biagini G, Avoli M.

J Physiol. 2008 Apr 1;586(7):1867-83. doi: 10.1113/jphysiol.2007.146159. Epub 2008 Jan 31.

47.

Subiculum network excitability is increased in a rodent model of temporal lobe epilepsy.

de Guzman P, Inaba Y, Biagini G, Baldelli E, Mollinari C, Merlo D, Avoli M.

Hippocampus. 2006;16(10):843-60.

PMID:
16897722
48.

Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy.

Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, Avoli M.

Exp Neurol. 2006 Oct;201(2):519-24. Epub 2006 Jun 14.

PMID:
16780839
49.

Impaired activation of CA3 pyramidal neurons in the epileptic hippocampus.

Biagini G, D'Arcangelo G, Baldelli E, D'Antuono M, Tancredi V, Avoli M.

Neuromolecular Med. 2005;7(4):325-42.

PMID:
16391389
50.

Synthesis of deserpidine from reserpine.

Varchi G, Battaglia A, Samorì C, Baldelli E, Danieli B, Fontana G, Guerrini A, Bombardelli E.

J Nat Prod. 2005 Nov;68(11):1629-31.

PMID:
16309312

Supplemental Content

Loading ...
Support Center